Clinical Trials Logo

Recurrent or Refractory Primary CNS Lymphoma clinical trials

View clinical trials related to Recurrent or Refractory Primary CNS Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00942747 Recruiting - Clinical trials for Recurrent or Refractory Primary CNS Lymphoma

Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

Start date: July 2009
Phase: Phase 2
Study type: Interventional

This is an open-label trial investigating the efficacy of temsirolimus in recurrent or refractory primary CNS lymphoma (PCNSL) after initial chemotherapy with a high-dose methotrexate containing regimen. 37 patients are planned to be treated with weekly infusions of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months. The trial is designed in two stages, if less than one of the first 12 patients responds to treatment, the trial is stopped. In addition to efficacy, safety and penetration of temsirolimus into the cerebrospinal fluid will be investigated.